Multiple Sclerosis Journal · 2007 · 16 citations · 6 references
Life SciencesHematologyNeurologyAutoimmunityImmunopathologyNeuroimmunologyAnemiaAutoimmune DiseasesAutoimmune Hematologic DiseaseInterferon-based TherapyMultiple SclerosisMultiple Sclerosis PharmacotherapyImmune-mediated Hemolytic AnemiaInterferon Alfa TherapyMultiple Sclerosis AssociationsMultiple Sclerosis ImmunopathogenesisMultiple Sclerosis ImmunopathologyMultiple Sclerosis TherapyPrednisone TaperingPrednisone Use
A 31-year-old patient with multiple sclerosis (MS), treated with interferon beta-1b (IFNB-1b) for two years, presented with fatigue and dizziness. Coombs' positive autoimmune hemolytic anemia (AIHA) was found. Other potential etiologies of AIHA were ruled out. An association with IFNB-1b was highly suspected. Interferon therapy was discontinued and prednisone therapy instituted. There was resolution of the hemolytic anemia, and prednisone therapy was tapered gradually. To the best of our knowledge, there is no reported case of the development of AIHA associated with IFNB-1b use in MS patients. We conclude that if an unexplained drop in hematocrit occurs with a MS patient receiving IFNB-1b, autoimmune mediated hemolysis should also be considered.
6
Exacerbation of symptoms of autoimmune disease in patients receiving alpha-interferon therapy
Kevin C. Conlon, Walter J. Urba, John W. Smithii et al. · Cancer · 1990 · 298 citations
Haematological Effects of Interferon-??-1a (Rebif??) Therapy in Multiple Sclerosis
Paul O Connor, Gordon Francis, Graham Wetherill et al. · Drug Safety · 2004 · 75 citations
Medicine, Hematology, Immunology +12
E. Verdun, G. Isoardo, Alessandra Oggero et al. · Journal of Interferon & Cytokine Research · 2002 · 31 citations
Life Sciences, Immunology, Neurology +17